调节性T淋巴细胞在预防与治疗移植物抗宿主病中的作用

Role of regulatory T lymphocytes in prevention and treatment of graft versus host disease

移植物抗宿主病（GVHD）为异基因造血干细胞移植（allo—HSCT）后，导致患者无复发死亡的重要原因。目前，预防与治疗GVHD的措施尚不完善，应用调节性T淋巴细胞（Treg）预防与治疗GVHD的方案已经进入临床研究阶段。Treg可以增强供者来源的效应性T淋巴细胞（Teff）对患者组织的免疫耐受，预防自身免疫反应，减低移植物排斥与GVHD的发生风险，但是同时可能减弱移植物抗白血病（GVL）效应。为了进一步探究Treg在GVHD预防与治疗中的作用，笔者拟就Treg的生物学特性，Treg预防与治疗GVHD的相关机制及其应用进展，以及Treg对GVL效应的影响进行阐述。

Graft versus host disease （GVHD） is a major cause of non-relapse mortality after allogeneic hematopoietic cell transplantation （allo-HSCT）. Existing strategies to prevent and treat GVHD are defective, and therapies involving the use of regulatory T cell （Treg） to control GVHD have emerged in clinical stage. Treg constitutes a population which is responsible for tolerance of effector T lymphocyte （Teff） to self-tissues in the immune system. Treg prevents autoimmune reactions and decreases the risk of rejection of grafts and GVHD, but may influence the graft versus leukemia （GVL） reaction. In order to explore role of Treg in prevention and treatment of GVHD, authors summarized literatures on recent advances in preventing and treating GVHD with Treg and its influence on GVL based on its biological characteristics.